The Gastroprotective Effect of DLBS2411 for High-Risk Gastrointestinal Patients: Case Series in Inflammatory Pain Condition

Rizaldy Taslim Pinzon; Abraham Al Jody; Nicholas Adriel Pinzon

doi:10.56951/6197xj25

The Gastroprotective Effect of DLBS2411 for High-Risk Gastrointestinal Patients: Case Series in Inflammatory Pain Condition

Penulis

Rizaldy Taslim Pinzon Neurology Department, School of Medicine, Duta Wacana Christian University, Yogyakarta, Indonesia
Abraham Al Jody Neurology Department, School of Medicine, Duta Wacana Christian University, Yogyakarta, Indonesia
Nicholas Adriel Pinzon Neurology Department, School of Medicine, Duta Wacana Christian University, Yogyakarta, Indonesia

DOI:

https://doi.org/10.56951/6197xj25

Kata Kunci:

pain, gastrointestinal, DLBS2411

Abstrak

Chronic pain is a common and distressing problem for the population. The cyclooxygenase (COX)-2 selective and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in managing acute and chronic pain. Research has provided a greater understanding of the risks of gastrointestinal, cardiovascular, and renal events associated with NSAID use. Proton pump inhibitors (PPIs) are widely prescribed due to their gastroprotective effects in NSAID users. However, PPIs also have several acid-inhibition-related and unrelated adverse effects that limit their use in high-risk patients. We report five patients suffering from painful inflammatory pain (flare rheumatoid arthritis, painful knee bursitis, and osteoarthritis). In this case series we evaluate the use of DLBS2411 as an alternative to PPIs. Our study suggests that DLBS2411 can be a safe alternative to PPIs for gastrointestinal high-risk patients who require anti-inflammatory agents.

Unduhan

Baca Selengkapnya

Referensi

1. Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. Br J Anaesth. 2019;123(2):e273-83.

2. Ho KY, Cardosa MS, Chaiamnuay S, Hidayat R, Ho HQT, Kamil O, et al. Practice advisory on the appropriate use of NSAIDs in primary care. J Pain Res. 2020;13:1925-39.

3. Ho KY, Gwee KA, Cheng YK, Yoon KH, Hee HT, Omar AR. Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice. J Pain Res. 2018;11:1937-48.

4. Rostom A, Moayyedi P, Hunt R; Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29(5):481-96.

5. Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134(4):937-44.

6. Bouziana SD, Tziomalos K. Clinical relevance of clopidogrel-proton pump inhibitors interaction. World J Gastrointest Pharmacol Ther. 2015;6(2):17-21.

7. Sehested TSG, Gerds TA, Fosbøl EL, Hansen PW, Charlot MG, Carlson N, et al. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med. 2018;283(3):268-81.

8. Tjandrawinata RR, Nailufar F. Gastroprotective effect of DLBS2411 bioactive fraction from Cinnamomum burmannii against ethanol-induced gastric damage in rats. J Exp Pharmacol. 2020;12:87-95.

9. Rustan J, Yulandi A, Tjandrawinata RR. Network pharmacology approach to investigate the molecular mechanism of DLBS2411 (Cinnamomum burmannii) as a gastritis treatment. J Appl Pharm Sci. 2024;14(09):255-63.

10. Tjandrawinata RR, Nailufar F, Arifin PF. Hydrogen potassium adenosine triphosphatase activity inhibition and downregulation of its expression by bioactive fraction DLBS2411 from Cinnamomum burmannii in gastric parietal cells. Int J Gen Med. 2013;6:807-15.